Show simple item record

dc.contributor.authorHillmen, P
dc.contributor.authorRawstron, A
dc.contributor.authorMunir, T
dc.contributor.authorBrock, K
dc.contributor.authorVincente, S
dc.contributor.authorJefferson, Y
dc.contributor.authorPaterson, K
dc.contributor.authorFox, C
dc.contributor.authorGribben, J
dc.contributor.authorBloor, Adrian
dc.contributor.authorSchuh, A
dc.contributor.authorForconi, F
dc.date.accessioned2017-08-25T10:39:34Z
dc.date.available2017-08-25T10:39:34Z
dc.date.issued2017
dc.identifier.citationThe initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory Cll shows acceptable safety and promising early indications of efficacy. 2017, 102(s2): 311 Haematologicaen
dc.identifier.urihttp://hdl.handle.net/10541/620521
dc.language.isoenen
dc.titleThe initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory Cll shows acceptable safety and promising early indications of efficacy.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUniv Leeds, Expt Haematol, Leedsen
dc.identifier.journalHaematologicaen


This item appears in the following Collection(s)

Show simple item record